Nykode Therapeutics AS (OSL:NYKD) EV-to-Revenue : -5.24 (As of Jun. 01, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Nykode Therapeutics AS EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Nykode Therapeutics AS's enterprise value is kr-458.68 Mil. Nykode Therapeutics AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was kr87.47 Mil. Therefore, Nykode Therapeutics AS's EV-to-Revenue for today is -5.24.

The historical rank and industry rank for Nykode Therapeutics AS's EV-to-Revenue or its related term are showing as below:

OSL:NYKD' s EV-to-Revenue Range Over the Past 10 Years
Min: -12.27 Med: 21.1 Max: 125.38
Current: -5.24

During the past 8 years, the highest EV-to-Revenue of Nykode Therapeutics AS was 125.38. The lowest was -12.27. And the median was 21.10.

OSL:NYKD's EV-to-Revenue is ranked better than
96.19% of 997 companies
in the Biotechnology industry
Industry Median: 7.44 vs OSL:NYKD: -5.24

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-01), Nykode Therapeutics AS's stock price is kr1.787. Nykode Therapeutics AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was kr0.26. Therefore, Nykode Therapeutics AS's PS Ratio for today is 6.90.

Nykode Therapeutics AS EV-to-Revenue Historical Data

The historical data trend for Nykode Therapeutics AS's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nykode Therapeutics AS EV-to-Revenue Chart

Nykode Therapeutics AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-Revenue

Get a 7-Day Free Trial

10.44

70.12

89.06

39.23

-2.62

Nykode Therapeutics AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-Revenue	Get a 7-Day Free Trial															29.33	53.44	5.14	-2.62	-4.42

Competitive Comparison of Nykode Therapeutics AS's EV-to-Revenue

For the Biotechnology subindustry, Nykode Therapeutics AS's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nykode Therapeutics AS's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nykode Therapeutics AS's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

Nykode Therapeutics AS EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Nykode Therapeutics AS's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	-458.684	/	87.465
	=	-5.24

Nykode Therapeutics AS's current Enterprise Value is kr-458.68 Mil.
Nykode Therapeutics AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr87.47 Mil.

Nykode Therapeutics AS (OSL:NYKD) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Nykode Therapeutics AS's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.787	/	0.259
	=	6.90

Nykode Therapeutics AS's share price for today is kr1.787.
Nykode Therapeutics AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.26.

Nykode Therapeutics AS EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nykode Therapeutics AS's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Nykode Therapeutics AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nykode Therapeutics AS (OSL:NYKD) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

VACBF:USA NYKDo:Sweden 5VB:Germany

Address

Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349

Website

https://www.nykode.com

Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need. It operates in United States of America.

Nykode Therapeutics AS Headlines

No Headlines